Evidence map›Paper›PMID 41723928›Full record

ArticleNeuroImage. Clinical2026

Advanced neuroimaging assessment of neurodegenerative dementia syndromes: A framework for comprehensive multimodal FDG-PET, MR-perfusion, and MR-diffusion analysis.

Joachim Strobel, Jan Kassubek, Wolfgang Thaiss, Sarah Straub-Anderl, Zeljko Uzelac, Sarah Jesse, Laura Michelberger, Christoph Solbach, Ambros J Beer, Meinrad Beer and 3 more

Abstract read
In one paragraph

Article in NeuroImage. Clinical, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Joachim StrobelDepartment of Nuclear Medicine, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany; Department of Diagnostic and Interventional Radiology, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany. Electronic address: Joachim.strobel@uni-ulm.de.
Jan KassubekDepartment of Neurology, University Hospital Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany.
Wolfgang ThaissDepartment of Nuclear Medicine, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany.
Sarah Straub-AnderlDepartment of Neurology, University Hospital Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany.
Zeljko UzelacDepartment of Neurology, University Hospital Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany.
Sarah JesseDepartment of Neurology, University Hospital Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany.
Laura MichelbergerDepartment of Diagnostic and Interventional Radiology, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany.
Christoph SolbachDepartment of Nuclear Medicine, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany.
Ambros J BeerDepartment of Nuclear Medicine, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany.
Meinrad BeerDepartment of Diagnostic and Interventional Radiology, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany.
Georg GrönDepartment of Psychiatry and Psychotherapy III, University Hospital Ulm, Leimgrubenweg 12-14, 89075 Ulm, Germany.
Hans-Peter MüllerDepartment of Nuclear Medicine, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany; Department of Diagnostic and Interventional Radiology, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany; Department of Neurology, University Hospital Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany.
Nico SollmannDepartment of Nuclear Medicine, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany; Department of Diagnostic and Interventional Radiology, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany; Department of Diagnostic and Interventional Neuroradiology, School of Medicine and Health, TUM Klinikum Rechts der Isar, Technical University of Munich, Ismaninger Str. 22, 81675 Munich, Germany; TUM-Neuroimaging Center, TUM Klinikum Rechts der Isar, Technical University of Munich, Ismaninger Str. 22, 81675 Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe reference for imaging in neurodegenerative dementia syndromes (NDS) is [

objectivesThe aim of the present study was to evaluate a new methodological approach integrating metabolic, perfusion, and microstructural parameters from simultaneous FDG-PET/MRI to reveal different imaging signatures for different NDS subtypes. MATERIALS AND

methods66 patients with NDS (Alzheimer's disease: 28; behavioral frontotemporal dementia: 10; semantic variant primary progressive aphasia (PPA): 8; non-fluent variant PPA: 11; logopenic variant PPA: 9) and 10 subjects with subjective cognitive deficits (SCD) underwent combined FDG-PET/MRI with pseudo-continuous arterial spin labeling (pCASL) and diffusion tensor imaging (DTI). Standardized uptake values (SUV), cerebral blood flow (CBF), and fractional anisotropy (FA) were used to separate a respective NDS subgroup from all other NDS subgroups and from SCD based on a support vector machine (SVM) applied on region of interest (ROI)-based parameters.

resultsWhite matter alterations directly adjacent to the regions of alterations in SUV and CBF were identified. The SVM analysis on ROI-based parameters reached accuracies between 81% and 94% for separating an NDS subgroup from all other NDS subgroups and from SCD.

conclusionsMultimodal neuroimaging by combination of FDG-PET and MRI shows potential to further advance the diagnostic spectrum in NDS. Since particularly early diagnosis of NDS remains key for effective treatment and management of patients with NDS, the present framework appears promising to be developed further until it aligns and integrates with clinical routine.

Indexed as

DementiaMultimodal ImagingNeurodegenerative DiseasesNeuroimagingPositron-Emission TomographyAgedAged, 80 and overAlzheimer DiseaseBrainDiffusion Tensor ImagingFemaleFluorodeoxyglucose F18HumansMagnetic Resonance ImagingMaleMiddle AgedFluorodeoxyglucose F18Arterial spin labelingDiffusion tensor imagingMagnetic resonance imagingNeurodegenerative diseasesPositron emission tomographySupport vector machine

Identifiers

PMID41723928
PMCPMC12945645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.